Inhibikase Therapeutics, Inc.
NASDAQ:IKTBiotechnology
+$0.06 today
- Market cap
- $193.57M
- Beta
- 0.97
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.52
Volume 0.43M
Average 1.03M
IKT Operating Cash Flow
Cash generated by the company's core business operations during the period.
Inhibikase Therapeutics, Inc.NASDAQ: IKT
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $12.06M (cash outflow) rose 193.9% year over year, ahead of the +84.4% change in trailing-twelve-month operating cash flow. Sequentially, it rose 60.5% from the prior quarter. Over 3 fiscal years it compounded at +17.0% a year.
Context
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +193.9% holds above the trailing-twelve-month pace of +84.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (27.79M) USD
- Year-over-year change
- -45.1%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (27.79M) | -45.1% |
| FY2024 | 2024-12-31 | (19.15M) | -5.9% |
| FY2023 | 2023-12-31 | (18.09M) | -4.2% |
| FY2022 | 2022-12-31 | (17.35M) | -21.4% |
| FY2021 | 2021-12-31 | (14.3M) | — |
Operating Cash Flow vs competitors
How IKT compares with its peers on the latest reported figures
- IKT's LTM Mar 2026 operating cash flow of $35.74M is the 2nd largest of the 8 companies compared; the peer median is $12.78M.
- Its year-over-year change of +84.4% is the highest of 7, against a peer median of +9.4%.
- Over three fiscal years its annual growth of +17.0% compares with a peer median of +3.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $87.53M | -39.9% | -3.4% | 70.7% | |
| LTM Mar 2026 | $35.74M | +84.4% | +17.0% | — | |
| LTM Mar 2026 | $33.46M | +84.2% | -11.8% | 446.5% | |
| LTM Mar 2026 | $20.25M | -34.9% | +9.9% | — | |
| LTM Mar 2026 | $12.78M | +74.6% | +16.9% | — | |
| LTM Mar 2026 | $9.5M | +49.4% | -16.1% | — | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $6.89M | -30.5% | +72.9% | — |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $3.9M | — | — | — |
| Peer median (excluding IKT) | $12.78M | +9.4% | +3.3% | 258.6% | |
Competitors are the stored peer set for IKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (14.79M) | (18.05M) | (19.03M) | (27.52M) | (48.26M) |
| Depreciation & Amortization | 0 | 6.72K | 177.4K | 26.27K | 60.5K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.53M | 458.15K | 500.15K | 8.14M | 15.31M |
| Change in Working Capital | (1.76M) | 171.18K | 234.76K | 204.93K | 55.93K |
| Accounts Receivables | (110.14K) | 70.26K | 39.88K | 0 | 0 |
| Inventory | 1.3M | 0 | 0 | 0 | 0 |
| Accounts Payables | (630.9K) | 61.4K | (504.41K) | 271.78K | 146.83K |
| Other Working Capital | (2.33M) | 39.53K | 699.28K | (66.85K) | (90.9K) |
| Other Non-Cash Items | 721.63K | 67K | 31.54K | 0 | 5.05M |
| Operating Cash Flow | (14.3M) | (17.35M) | (18.09M) | (19.15M) | (27.79M) |
| Capital Expenditures | 1 | (243.26K) | (14.24K) | 0 | (13.4K) |
| Acquisitions (Net) | 0 | 243.26K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (20.73M) | (29.43M) | (60.46M) | (39.09M) |
| Sales of Investments | 0 | 4.96M | 41.1M | 23.45M | 41.6M |
| Other Investing Activities | 0 | (243.26K) | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (16.01M) | 11.66M | (37M) | 2.05M |
| Debt Repayment | (42.53K) | (248.91K) | 0 | 0 | 0 |
| Common Stock Issued | 41.14M | 44.14K | 8.54M | 103.48M | 108.46M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 848 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 41.09M | (204.77K) | 8.41M | 103.48M | 108.46M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 26.8M | (33.56M) | 1.98M | 47.33M | 82.73M |
| Free Cash Flow | (14.3M) | (17.59M) | (18.1M) | (19.15M) | (27.79M) |
Inhibikase Therapeutics, Inc.
NASDAQ:IKT
Intrinsic Alpha fair value
Locked
Current Price
$1.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.